Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not …

SM Dunlay, MM Givertz, D Aguilar, LA Allen, M Chan… - Circulation, 2019 - Am Heart Assoc
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?

A Sharma, S Verma, DL Bhatt, KA Connelly… - Basic to Translational …, 2022 - jacc.org
Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …

Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis

H Burnett, A Earley, AA Voors, M Senni… - Circulation: Heart …, 2017 - Am Heart Assoc
Background—Treatments that reduce mortality and morbidity in patients with heart failure
with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI) …

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

K Fox, I Ford, PG Steg, M Tendera, R Ferrari - The Lancet, 2008 - thelancet.com
Background Ivabradine specifically inhibits the I f current in the sinoatrial node to lower heart
rate, without affecting other aspects of cardiac function. We aimed to test whether lowering …

Conventional heart failure therapy in cardiac ATTR amyloidosis

A Ioannou, P Massa, RK Patel, Y Razvi… - European Heart …, 2023 - academic.oup.com
Aims The aims of this study were to assess prescription patterns, dosages, discontinuation
rates, and association with prognosis of conventional heart failure medications in patients …

Chronic kidney disease as a comorbidity in heart failure

M Szlagor, J Dybiec, E Młynarska, J Rysz… - International Journal of …, 2023 - mdpi.com
Heart failure (HF) is one of the greatest problems in healthcare and it often coexists with
declining renal function. The pathophysiology between the heart and the kidneys is …

Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and …

PG Shekelle, MW Rich, SC Morton… - Journal of the American …, 2003 - jacc.org
Objectives: This study sought to assess the effect of angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers on all-cause mortality in patients with left ventricular (LV) …

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995

K MacIntyre, S Capewell, S Stewart, JWT Chalmers… - Circulation, 2000 - Am Heart Assoc
Background—Contemporary survival in unselected patients with heart failure and the
population impact of newer therapies have not been widely studied. Therefore, we have …

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in …

A Ducharme, K Swedberg, MA Pfeffer… - American heart …, 2006 - Elsevier
BACKGROUND: Atrial fibrillation (AF) is frequent in patients with chronic heart failure (CHF).
Experimental and small patient studies have demonstrated that blocking the renin …

Emerging topics update of the Brazilian heart failure Guideline–2021

FG Marcondes-Braga, LAZ Moura, VS Issa… - Arquivos brasileiros de …, 2021 - SciELO Brasil
The latest Heart Failure Guidelines by the Department of Heart Failure of the Brazilian
Society of Cardiology (DEIC/SBC) were finalized on March 2018. Since then, a significant …